Alzheimer's Disease Lysosomal and Proteostasis Modulation Companies

Overview

flowchart TD
    companies_ad_lysosomal_proteos["Alzheimers Disease Lysosomal and Proteostasis Mo"]
    companies_ad_lysosomal_proteos["category"]
    companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
    style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
    companies_ad_lysosomal_proteos["covers"]
    companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
    style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
    companies_ad_lysosomal_proteos["biotechnology"]
    companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
    style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
    companies_ad_lysosomal_proteos["pharmaceutical"]
    companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
    style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
    style companies_ad_lysosomal_proteos fill:#4fc3f7,stroke:#333,color:#000

This category covers biotechnology and pharmaceutical companies developing therapeutics that target lysosomal dysfunction, autophagy impairment, and proteostasis network disruption in Alzheimer’s disease. These approaches address the fundamental cellular protein clearance and organelle maintenance deficits that are central to AD pathogenesis.

Lysosomal dysfunction is one of the earliest features of Alzheimer’s disease, preceding clinical symptoms by decades. Impairments in lysosomal acidification, reduced enzyme activity, and impaired autophagosome-lysosome fusion lead to accumulation of damaged proteins and organelles. The proteostasis network — comprising molecular chaperones, the ubiquitin-proteasome system, and autophagy-lysosomal pathways — becomes progressively overwhelmed in AD, contributing to amyloid-beta and tau aggregation.

Key Companies

Lysosomal Enzyme Enhancement

Gain Therapeutics

• Focus: Glucocerebrosidase (GCase) modulators and therapeutic chaperones

• Lead Candidate: GT-02287

• Indication: Alzheimer’s disease (preclinical), Parkinson’s disease (Phase 1b)

• Mechanism: Allosteric small molecule chaperones that stabilize misfolded GCase, enhancing lysosomal enzyme activity and reducing glycosphingolipid accumulation

• Platform: SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules)

• Page: Gain Therapeutics

Lysoway Therapeutics

• Focus: Lysosomal enzyme modulation and integrity

• Lead Candidates: LT-001, LT-002, LT-003

• Indication: Alzheimer’s disease, Parkinson’s disease

• Mechanism: Small molecule GCase modulators, autophagy enhancers, and lysosomal membrane protectors

• Stage: Discovery/Preclinical

• Page: Lysoway Therapeutics

Autophagy Induction

Retro Biosciences

• Focus: Autophagy enhancement and cellular clearance

• Lead Candidate: RB-001

• Indication: Alzheimer’s disease

• Stage: Phase 1

• Mechanism: Macroautophagy enhancement to clear protein aggregates and damaged organelles

• Notes: Also developing senolytic approaches

• Page: Retro Biosciences

Lyterian Therapeutics

• Focus: Autophagy modulation

• Lead Candidate: LTN-001

• Indication: Alzheimer’s disease

• Stage: Preclinical

• Mechanism: mTOR-independent autophagy enhancers targeting TFEB pathway

Proteasome Modulation

Proteostasis Therapeutics

• Focus: Ubiquitin-proteasome system modulation

• Lead Candidate: PT-101

• Indication: Alzheimer’s disease, Parkinson’s disease

• Stage: Preclinical

• Mechanism: Selective 20S proteasome activators to enhance protein clearance

• Page: Proteostasis Therapeutics

Molecular Chaperone Modulation

Iduna Therapeutics

• Focus: Heat shock protein (HSP) modulators

• Lead Candidate: IDN-001

• Indication: Alzheimer’s disease, Parkinson’s disease

• Stage: Preclinical

• Mechanism: HSP70 modulators to enhance protein refolding and clearance; HSP90 selective inhibition

• Page: Iduna Therapeutics

Lysosomal-TREM2 Biology

Alector Inc.

• Focus: TREM2 agonists and lysosomal function

• Lead Candidates: AL002, AL044

• Indication: Alzheimer’s disease

• Stage: Phase 1/2

• Mechanism: TREM2 agonism to enhance microglial lysosomal function, phagocytosis, and clearance of amyloid plaques

• Page: Alector

Computational/AI Approaches

Cyclica

• Focus: AI-driven protein homeostasis drug discovery

• Lead Candidates: CC-201, CC-202, CC-203

• Indication: Alzheimer’s disease

• Stage: Phase 1/Preclinical

• Mechanism: Protein homeostasis modulators, tau aggregation inhibitors, molecular chaperone enhancers

• Platform: MatchMaker™ AI technology

• Page: ^{1Cyclica - AI-Driven Drug DiscoveryOpen reference}(/companies/cyclica)

Additional Companies

Therapeutic Mechanisms

Lysosomal Targeting Approaches

1. Therapeutic Chaperones: Small molecules that stabilize lysosomal enzyme conformations, enhancing activity (e.g., Gain Therapeutics)

2. Lysosomal Acidification: Compounds that restore lysosomal pH gradient and enzyme activity

3. Enzyme Replacement: Recombinant lysosomal enzymes delivered via gene therapy or protein delivery

4. Substrate Reduction: Reducing accumulation of glycosphingolipids that impair lysosomal function

Autophagy Enhancement

1. mTOR Inhibition: Rapamycin analogs that induce macroautophagy

2. mTOR-Independent Enhancement: TFEB pathway activation through alternative mechanisms

3. Autophagy Adaptor Modulation: Enhancing cargo recognition and autophagosome formation

4. Mitophagy Enhancement: PINK1/Parkin pathway activation to clear damaged mitochondria

Proteostasis Network

1. Molecular Chaperone Modulation: HSP70/HSP90 modulators to enhance protein folding

2. Proteasome Activation: Selective 20S proteasome activators for protein clearance

3. Ubiquitin System: E3 ligase modulators to enhance protein tagging for degradation

4. Chaperone-Mediated Autophagy: LAMP-2A modulators for selective protein clearance

Pipeline Summary

Research Context

Lysosomal Dysfunction in Alzheimer’s Disease

Lysosomal dysfunction is a hallmark of Alzheimer’s disease:

• Acidification Defects: Reduced V-ATPase activity impairs lysosomal acidification

• Enzyme Deficiency: Reduced cathepsin activity degrades protein clearance capacity

• Autophagosome Accumulation: Impaired fusion between autophagosomes and lysosomes

• Lipid Accumulation: Glucosylceramide and other lipids accumulate, disrupting function

• GBA1 Connection: GBA1 mutations (linked to PD) may also increase AD risk

Autophagy Impairment in AD

The autophagy-lysosomal system shows specific defects in AD:

• Early Impairment: Autophagy induction declines before amyloid pathology

• TFEB Dysregulation: Master regulator of lysosomal biogenesis is suppressed

• Impaired Flux: Autophagosomes accumulate but fail to fuse with lysosomes

• Amyloid Clearance: Reduced capacity to clear amyloid-beta aggregates

• Tau Clearance: Impaired autophagy contributes to tau tangle formation

Proteostasis Network Collapse

The proteostasis network becomes progressively overwhelmed:

• Chaperone Capacity: HSP70/90 systems become saturated with misfolded proteins

• Proteasome Inhibition: 20S proteasome activity reduced in AD brains

• Ubiquitin Accumulation: Excess ubiquitin conjugates indicate overwhelmed degradation

• Aggregation Seeding: Misfolded proteins seed toxic aggregate formation

Cross-Links

• Lysosomal Dysfunction in Alzheimer’s Disease

• Autophagy in Neurodegeneration

• Protein Homeostasis Network

• Mitochondrial Dysfunction in Alzheimer’s Disease

• Amyloid Cascade Hypothesis

• Tau Pathology

• AD Pipeline Companies

• AD Mitochondria-Targeting Companies

• AD Senolytic Therapy Companies